Interim Phase 2 Trial Data of Kidney Disease Drug DMX-200 to Be Reported by Dimerix
News
Australian biotech company Dimerix Limited will soon report interim data from its Phase 2 clinical study of DMX-200 in patients with chronic kidney disease (CKD), after 10 patients have been dosed in ... Read more